All In Biotech

Drug Trial Radar · NCT04108156

A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME

A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema (Pagoda)

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 672 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

672

Actual

Start

Sep 30, 2019

Primary completion

Jul 20, 2027

Study completion Jul 20, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Sep 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety, and Pharmacokinetics (PK) of the PDS with ranibizumab in participants with DME when treated every 24 weeks (Q24W) compared with intravitreal (IVT) ranibizumab 0.5 milligrams (mg) every 4 weeks (Q4W). The substudy will evaluate safety of re-implanting the updated PDS with ranibizumab and the refill-exchange procedures following re-implantation in participants with DME who were previously enrolled in the main study, GR40550. Up to 100 participants from the main study will be enrolled and followed for a maximum of 72 weeks post-re-implantation in the substudy.

Conditions

  • Diabetic Macular Edema

Interventions

  • PDS Implant Pre-Filled with 100 mg/mL RanibizumabDrug

    Will be administered as per the schedule described in individual arm.

  • Intravitreal Ranibizumab 0.5 mg InjectionDrug

    Will be administered as per the schedule described in individual arm.

  • Ranibizumab refill exchangeDrug

    Will be administered as per the schedule described in individual arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in BCVA Score From Baseline Averaged Over Weeks 60 and 64 as Measured Using the ETDRS Chart in the Efficacy Population Using a Treatment Policy Strategy for all Intercurrent EventsTime frame: Baseline to Week 64
  2. Substudy: Number of Participants With Ocular and Systemic (Non-ocular) Adverse Events (AEs) and Severity of Ocular and Systemic AEsTime frame: Baseline to Week 72
  3. Substudy: Number of Participants With Adverse Events of Special Interests (AESIs) and Severity of AESIsTime frame: Baseline to Week 72
  4. Substudy: Duration of AESIsTime frame: Baseline to Week 72
  5. Substudy: Number of Participants With Ocular AESIs and Severity of Ocular AESIs During the Post-operative PeriodTime frame: Up to Day 37 post re-implantation
  6. Substudy: Number of Participants With Ocular AESIs and Severity of Ocular AESIs During the Follow-up PeriodTime frame: > 37 days post-implantation (up to approximately 72 weeks)
  7. Substudy: Duration of Ocular AESIs During the Post-operative PeriodTime frame: Up to Day 37 post re-implantation
  8. Substudy: Duration of Ocular AESIs During the Follow-up PeriodTime frame: > 37 days post-implantation (up to approximately 72 weeks)
  9. Substudy: Number of Participants With Adverse Device Effects (ADEs) and Severity of ADEsTime frame: Baseline to Week 72
  10. Substudy: Number of Participants With Anticipated Serious ADEsTime frame: Baseline to Week 72
  11. Substudy: Duration of Serious ADEsTime frame: Baseline to Week 72
  12. Substudy: Number of Device DeficienciesTime frame: Baseline to Week 72

Locations

89 sites in 1 country. Site status is shown where the registry gives one.

  • Barnet Dulaney Perkins Eye Center

    Mesa, Arizona

  • Retinal Consultants of Arizona;Opthalmology

    Phoenix, Arizona

  • Arizona Retina and Vitreous Consultants

    Phoenix, Arizona

  • Associated Retina Consultants

    Phoenix, Arizona

  • California Retina Consultants

    Bakersfield, California

  • Retina-Vitreous Associates Medical Group

    Beverly Hills, California

  • The Retina Partners

    Encino, California

  • Retina Consultants of Orange County;Clinical Research

    Fullerton, California

  • Jules Stein Eye Institute/ UCLA

    Los Angeles, California

  • Northern California Retina-Vitreous Associates

    Mountain View, California

  • East Bay Retina Consultants

    Oakland, California

  • Doheny Eye Institute

    Pasadena, California

  • California Eye Specialists Medical Group

    Pasadena, California

  • Retina Consultants Medical Group

    Sacramento, California

  • Zuckerberg San Francisco General Hospital and Trauma Center

    San Francisco, California

  • Orange County Retina Medical Group

    Santa Ana, California

  • California Retina Consultants;Research Department

    Santa Barbara, California

  • Eye Center of Northern Colorado

    Fort Collins, Colorado

  • Colorado Clinical Research

    Lakewood, Colorado

  • Retina Group of New England

    Waterford, Connecticut

  • Retina Group of Florida

    Fort Lauderdale, Florida

  • National Ophthalmic Research Institute

    Fort Myers, Florida

  • Retina Specialty Institute

    Pensacola, Florida

  • Fort Lauderdale Eye Institute

    Plantation, Florida

  • Retina Vitreous Associates of Florida

    St. Petersburg, Florida

  • Southern Vitreoretinal Associates;Research

    Tallahassee, Florida

  • Retina Associates of Florida;Retina Associates of Florida

    Tampa, Florida

  • Southeast Retina Center

    Augusta, Georgia

  • Georgia Retina

    Marietta, Georgia

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • Illinois Retina Associates

    Joliet, Illinois

  • University Retina

    Lemont, Illinois

  • Wolfe Eye Clinic

    West Des Moines, Iowa

  • Retina Associates

    Lenexa, Kansas

  • Retina & Vitreous Associates of Kentucky

    Lexington, Kentucky

  • Maine Eye Center

    Portland, Maine

  • The Retina Care Center

    Baltimore, Maryland

  • Johns Hopkins Hospital;Johns Hopkins Med;Wilmer Eye Inst

    Baltimore, Maryland

  • The Retina Group of Washington;Retinal Disease

    Chevy Chase, Maryland

  • Cumberland Valley Retina Consultants;Clinical Research

    Hagerstown, Maryland

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.